Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report published on Monday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Down 10.0 %

Shares of NASDAQ ADXS opened at $0.03 on Monday. The stock has a market capitalization of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.62. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49. The firm has a 50-day moving average price of $0.04 and a 200 day moving average price of $0.05.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.